Shalby Ltd
Shalby Ltd is engaged in healthcare delivery space in India. It operates a chain of multi-specialty hospitals across India. The business of the company is to offer tertiary and quaternary healthcare services to patients in various areas of specialization such as orthopaedics, complex joint replacements, cardiology, neurology, oncology, renal transplantations, etc.[1]
The company is the global leader in knee replacement surgery and one of the top Indian hospitals in joint replacement surgery.
- Market Cap ₹ 3,006 Cr.
- Current Price ₹ 278
- High / Low ₹ 340 / 174
- Stock P/E 28.9
- Book Value ₹ 98.3
- Dividend Yield 0.44 %
- ROCE 14.8 %
- ROE 10.2 %
- Face Value ₹ 10.0
Pros
- Company has delivered good profit growth of 26.5% CAGR over last 5 years
Cons
- Stock is trading at 2.81 times its book value
- Company has a low return on equity of 9.02% over last 3 years.
- Working capital days have increased from 88.7 days to 144 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Healthcare
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2010 | Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
101 | 132 | 241 | 263 | 322 | 380 | 462 | 484 | 419 | 647 | 708 | 830 | |
89 | 107 | 177 | 192 | 250 | 300 | 379 | 401 | 331 | 516 | 564 | 652 | |
Operating Profit | 13 | 25 | 64 | 70 | 73 | 80 | 84 | 83 | 88 | 131 | 144 | 178 |
OPM % | 12% | 19% | 27% | 27% | 23% | 21% | 18% | 17% | 21% | 20% | 20% | 21% |
1 | 1 | 3 | 2 | 6 | 10 | 9 | 18 | 9 | 9 | 19 | 21 | |
Interest | 1 | 0 | 2 | 5 | 11 | 12 | 9 | 7 | 4 | 4 | 4 | 3 |
Depreciation | 5 | 5 | 10 | 20 | 16 | 22 | 33 | 36 | 37 | 36 | 37 | 37 |
Profit before tax | 8 | 21 | 56 | 47 | 52 | 55 | 51 | 57 | 55 | 100 | 121 | 158 |
Tax % | 27% | 34% | 26% | 39% | 42% | 26% | 37% | 51% | 23% | 30% | 33% | 34% |
6 | 14 | 41 | 28 | 30 | 40 | 32 | 28 | 43 | 70 | 81 | 104 | |
EPS in Rs | 2.65 | 5.47 | 11.79 | 8.15 | 3.47 | 3.75 | 2.97 | 2.59 | 3.97 | 6.46 | 7.48 | 9.61 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 17% | 19% | 25% | 15% | 16% | 12% |
Compounded Sales Growth | |
---|---|
10 Years: | 13% |
5 Years: | 12% |
3 Years: | 26% |
TTM: | 17% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | 26% |
3 Years: | 34% |
TTM: | 30% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 14% |
1 Year: | 51% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 7% |
3 Years: | 9% |
Last Year: | 10% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2010 | Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 25 | 35 | 35 | 87 | 108 | 108 | 108 | 108 | 108 | 107 | 107 |
Reserves | 12 | 23 | 111 | 137 | 171 | 657 | 686 | 706 | 742 | 799 | 863 | 955 |
Preference Capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
4 | 0 | 37 | 98 | 325 | 114 | 71 | 62 | 44 | 41 | 26 | 121 | |
24 | 19 | 33 | 77 | 99 | 96 | 91 | 105 | 119 | 139 | 172 | 190 | |
Total Liabilities | 62 | 67 | 215 | 347 | 682 | 975 | 956 | 981 | 1,012 | 1,087 | 1,167 | 1,374 |
33 | 31 | 105 | 144 | 312 | 647 | 689 | 670 | 658 | 628 | 603 | 599 | |
CWIP | 0 | 0 | 5 | 91 | 221 | 47 | 3 | 6 | 8 | 6 | 10 | 5 |
Investments | 4 | 6 | 19 | 26 | 10 | 10 | 24 | 43 | 32 | 62 | 313 | 511 |
25 | 30 | 86 | 86 | 139 | 270 | 239 | 262 | 315 | 391 | 242 | 258 | |
Total Assets | 62 | 67 | 215 | 347 | 682 | 975 | 956 | 981 | 1,012 | 1,087 | 1,167 | 1,374 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2010 | Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 7 | 71 | 15 | 46 | 57 | 77 | 101 | 165 | 140 | |||
-6 | -5 | -157 | -241 | -0 | -32 | -52 | -40 | -172 | -206 | |||
1 | -3 | 89 | 226 | -51 | -22 | -28 | -17 | -38 | 72 | |||
Net Cash Flow | 3 | -1 | 3 | -1 | -6 | 3 | -2 | 43 | -46 | 6 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2010 | Mar 2011 | Mar 2014 | Mar 2015 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 34 | 25 | 21 | 28 | 38 | 48 | 64 | 69 | 81 | 53 | 46 | 52 |
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 34 | 25 | 21 | 28 | 38 | 48 | 64 | 69 | 81 | 53 | 46 | 52 |
Working Capital Days | -19 | 16 | 41 | -60 | -28 | 0 | 61 | 73 | 87 | 82 | 40 | 144 |
ROCE % | 48% | 23% | 9% | 7% | 7% | 7% | 12% | 13% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
1d - Investors Conference Call scheduled on July 9, 2024 at 4:00 pm. IST to discuss Unaudited Financial Results for quarter ended June 30, 2024
- Board Meeting Intimation for Considering And Approving The Un-Audited Financial Results (Standalone And Consolidated) Of The Company For The Quarter Ended June 30, 2024 And Other Business Matters 29 Jun
- Closure of Trading Window 26 Jun
- Termination Of Franchise Agreement 24 Jun
- Intimation For Availing Of SBLC And Working Capital Facilities 11 Jun
Annual reports
Concalls
-
Jun 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jun 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Dec 2021Transcript PPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
May 2021Transcript PPT
-
May 2021TranscriptNotesPPT
-
May 2021TranscriptNotesPPT
-
Jan 2021Transcript PPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptPPT
-
Oct 2020Transcript PPT
-
Sep 2020TranscriptNotesPPT
-
Jun 2020Transcript PPT
-
Feb 2020Transcript PPT
-
Nov 2019Transcript PPT
-
Jul 2019Transcript PPT
-
May 2019Transcript PPT
-
Jan 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Mar 2018TranscriptNotesPPT
Hospitals Portfolio
The co. operates 14 hospitals across India with a total bed capacity of 2,000+ beds. It also owns 60 outpatient clinics across 16 states in India and 5 OP clinics in African Countries. [1] [2] The co. has two upcoming facilities with a combined capacity of 321 beds will be located in Maharashtra. [3]